Welcome to our dedicated page for Lantern Pharma news (Ticker: LTRN), a resource for investors and traders seeking the latest updates and insights on Lantern Pharma stock.
Lantern Pharma Inc. (NASDAQ: LTRN) generates a steady flow of news as an AI-driven, clinical-stage oncology company advancing both a precision medicine pipeline and a proprietary artificial intelligence platform. News coverage on this page centers on developments in its RADR® AI and machine learning platform, clinical trial milestones for LP-184, LP-284, and LP-300, regulatory interactions, and strategic initiatives that shape the company’s position in AI-enabled cancer drug development.
Investors and researchers following LTRN news will find detailed updates on Phase 1 and Phase 2 clinical trials, including safety and efficacy readouts, biomarker findings, and disease control observations in heavily pre-treated cancer patients. Recent announcements have highlighted LP-184’s Phase 1a results in advanced solid tumors, LP-284’s activity in relapsed or refractory B-cell lymphomas, and LP-300 data from the HARMONIC™ trial in never-smoker non-small cell lung cancer. Lantern also reports on FDA designations such as Fast Track, Orphan Drug, and Rare Pediatric Disease status that influence development pathways for its drug candidates.
In addition to clinical results, Lantern’s news stream covers the evolution of its RADR® platform and related AI modules. Articles describe the launch and performance of tools like predictBBB.ai for blood–brain barrier prediction and LBx-AI for liquid biopsy-based treatment response modeling, as well as presentations at scientific meetings and symposia. Corporate news items include quarterly financial updates, at-the-market financing agreements, board appointments, proxy statements, and the announcement of an AI Center of Excellence in Bengaluru, India to scale RADR® and multi-agent AI systems for global biopharma partners.
By reviewing the LTRN news feed, readers can track how Lantern integrates AI, genomics, and clinical data into its oncology programs, how regulators and collaborators engage with its pipeline, and how the company positions its AI modules and partnerships in the broader biopharmaceutical landscape. This page is a resource for monitoring material events, clinical inflection points, and platform advances that Lantern discloses through press releases and regulatory communications.
Lantern Pharma Inc. (NASDAQ: LTRN) is enhancing its RADR® platform to support the development of Antibody Drug Conjugates (ADCs). This initiative aims to advance ADC candidates to first-in-human trials in around two years, bolstered by a library of over 200 algorithms and 25 billion oncology-focused data points. The ADC market, currently valued at over $4 billion, is projected to grow to $14 billion by 2027. The expansion includes new AI and ML strategies for drug candidate identification, patient stratification, and improved payload delivery, positioning Lantern for significant business development opportunities.
Lantern Pharma (NASDAQ: LTRN) has received FDA guidance for its LP-184 program aimed at treating various cancers, including CNS cancers. The feedback aligns with Lantern's plans for an IND submission and a first-in-human clinical trial scheduled for Q2 2023. LP-184 demonstrates significant potency against multiple cancers and aims to improve outcomes for patients with high unmet needs. The trial will focus on pancreatic cancer and glioblastoma, leveraging Lantern's RADR® AI platform for patient identification. The company anticipates impactful results that could benefit both patients and shareholders.
Lantern Pharma (NASDAQ: LTRN) announced that the FDA has granted Orphan Drug Designation for LP-284, aimed at treating mantle cell lymphoma (MCL). This designation enhances LP-284’s clinical development and offers seven years of market exclusivity. Lantern expects to file an IND and begin a Phase 1 trial for LP-284 in MCL by mid-2023. MCL affects around 4,500 patients annually in the U.S., with a market potential of $600 million. The drug demonstrated significant anti-tumor activity in preclinical models, particularly against resistant tumors.
Lantern Pharma (NASDAQ: LTRN) released positive preclinical data for LP-284, targeting Mantle Cell Lymphoma (MCL), presented at the American Society of Hematology Meeting. The data indicates LP-284's superior tumor growth inhibition compared to traditional therapies like Ibrutinib and Bortezomib, achieving a TGI of 113%. Lantern plans to file an IND with the FDA in early 2023 and initiate a Phase 1 trial mid-2023. MCL and double hit lymphoma (DHL) represent about 9,000 new cases annually, with a market potential of $1.2 billion USD.
Lantern Pharma Inc. (NASDAQ: LTRN) announced significant findings at the SABCS 2022, highlighting the promising anti-tumor effects of its drug candidate LP-184 against Triple Negative Breast Cancer (TNBC). LP-184 demonstrated an average IC50 of 297nM across four TNBC cell lines and achieved a remarkable 107-141% tumor regression in 10 resistant tumor models. The annual market for TNBC represents approximately $1.7 billion USD. The expansion of LP-184's indications may enhance its long-term value and address unmet needs in solid tumors.
Lantern Pharma (NASDAQ: LTRN) announced that CEO Panna Sharma will present at the RHK Capital Disruptive Growth Conference in New York City on December 5, 2022, at 12:00 p.m. ET. This conference will showcase around 30 innovative companies, connecting them with institutional and accredited investors.
Lantern Pharma leverages its RADR® AI platform for oncology drug development, focusing on genomically-targeted therapies, with four candidates in progress.
Lantern Pharma (NASDAQ: LTRN) announced positive preclinical data for its drug candidate LP-184 targeting glioblastoma (GBM) at the Society for Neuro-Oncology annual meeting. The study showed LP-184's efficacy either alone or combined with spironolactone, outperforming the standard treatment Temozolomide (TMZ) in resistant models. LP-184 has the potential market of $1.5-2.0 billion, with ongoing collaborative research with Johns Hopkins aimed at advancing it to clinical trials in 2023. The drug holds Orphan Drug and Rare Pediatric Disease designations, emphasizing its potential in oncology.
Lantern Pharma (NASDAQ: LTRN) reported third quarter results for 2022, activating two sites for the Harmonic™ clinical trial in never-smoker patients with NSCLC. The completion of IND-enabling studies for LP-184 and LP-284 is anticipated in Q1 2023, with Phase 1 trials planned for H1 2023. As of September 30, 2022, Lantern held $57.8 million in cash, reflecting a net decrease of $4.3 million during the quarter. Despite a net loss of $2.3 million, a significant reduction from $4.1 million year-over-year, the company maintains a cash runway into 2025.
Lantern Pharma (NASDAQ: LTRN), a clinical-stage biopharmaceutical company, announced its participation in two investor conferences. The BioFuture Conference will take place in New York, NY on November 8, 2022, with presentations by CEO Panna Sharma and CFO David Margrave at 2:00 p.m. ET. The Disruptive Growth Conference is set for December 5-6, 2022, with the time for Sharma's presentation to be announced. Lantern Pharma is advancing oncology drug discovery through its proprietary RADR® platform, targeting customized therapeutics for diverse tumor profiles.
Lantern Pharma Inc. (NASDAQ: LTRN) will host its third quarter 2022 financial results webcast on November 7, 2022 at 4:30 p.m. ET. The management, led by CEO Panna Sharma, will discuss the operating and financial results from the third quarter ended September 30, 2022, alongside future milestones. Lantern Pharma focuses on oncology drug discovery using its proprietary RADR® A.I. platform to identify patient populations likely to benefit from its drug candidates, including four candidates and an ADC program across nine tumor targets.